These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1530533)

  • 21. A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851.
    Gottlieb AJ; Anderson JR; Ginsberg SJ; Bloomfield CD; Norton L; Barcos M; Peterson BA; Nissen N; Henderson ES; Holland JF
    Cancer; 1990 Nov; 66(9):1888-96. PubMed ID: 1699653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study.
    Takagi T; Sampi K; Sawada U; Sakai C; Oguro M
    Int J Hematol; 1993 Jan; 57(1):67-71. PubMed ID: 8477064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
    Linch DC; Smith P; Hancock BW; Hoskin PJ; Cunningham DC; Newland AC; Milligan D; Stevenson PA; Wood JK; Maclennan KA; Vaughan B; Vaughan G; Gregory WM
    Ann Oncol; 2000; 11 Suppl 1():87-90. PubMed ID: 10707786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin's lymphomas: a phase II multicentre study.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Lennert K; Wellens W; Schmidt M; Gassel WD; Kolb T; Hässler R
    Br J Cancer; 1989 Jul; 60(1):79-82. PubMed ID: 2679846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive treatment of stage III-IV aggressive malignant lymphomas (protocol TPL-84).
    Colombat P; Guilhot F; Bordesoule D; Renou P; Benz-Lemoine E; Fouillard L; Drouet M; Tanzer J; Lamagnere JP
    Haematologica; 1991; 76(6):479-84. PubMed ID: 1726492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effective multi-agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood.
    Toogood IR; Tiedemann K; Stevens M; Smith PJ
    Med Pediatr Oncol; 1993; 21(2):103-10. PubMed ID: 8433675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
    Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
    Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL).
    Silingardi V; Federico M; Cavanna L; Avanzini P; Gobbi PG; Lombardo M; Carotenuto M; Frassoldati A; Pieresca C; Vallisa D
    Leuk Lymphoma; 1995 Apr; 17(3-4):313-20. PubMed ID: 8580801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
    Steinke B; Kraft A; Reinold HM; Heim ME; Löffler B; Heidemann E; Richter C; Josten K; Bross K; Hofmann I
    Onkologie; 1989 Feb; 12(1):19-21. PubMed ID: 2469999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
    Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
    J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
    Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
    Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Alternating CHOP-MEVP chemotherapy for advanced-stage, intermediate- and high-grade non-Hodgkin's lymphomas].
    Takagi T; Sakai C; Oguro M
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2191-4. PubMed ID: 8239684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of refractory lymphoma with methotrexate, VM-26 (teniposide), procarbazine, and dexamethasone: Cancer and Leukemia Group B study 7902.
    Lachant NA; Anderson J; Ginsberg SJ; Cooper MR; Hurd DD; Bloomfield CD; Gottlieb AJ
    Med Pediatr Oncol; 1988; 16(6):375-7. PubMed ID: 3264379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.